A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
RHYTHM PHARMACEUTICALS, INC.
RYTM
$6.6B
Mkt Cap
$102.10
-0.55%
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a 5-year average return on invested capital (ROIC) of -64.5%. This is below average and may indicate limited pricing power.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a market capitalization of $6.6B. It is classified as a mid-cap stock.
RHYTHM PHARMACEUTICALS, INC. (RYTM) does not currently pay a regular dividend.
RHYTHM PHARMACEUTICALS, INC. (RYTM) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported annual revenue of $190 million in its most recent fiscal year, based on SEC EDGAR filings.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a net profit margin of -106.4%. The company is currently unprofitable.
RHYTHM PHARMACEUTICALS, INC. (RYTM) generated $-117 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE® (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subset of individuals who have hyperphagia, a pathological, insatiable hunger and impaired satiety accompanied by persistent and abnormal food-seeking behaviors, decreased energy expenditure and severe obesity due to diseases such as acquired or congenital hypothalamic obesity, Bardet-Biedl syndrome (BBS), Prader-Willi syndrome (PWS) and other diseases caused by impaired MC4R pathway signaling.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 190M | 190M | - | - | - | - |
| Net Income | -202M | -202M | -265M | -185M | -181M | -70M |
| EPS | $-3.11 | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Free Cash Flow | -117M | -117M | -114M | -136M | -174M | -146M |
| ROIC | -74.3% | -109.2% | -53.5% | -66.9% | -68.5% | -24.3% |
| Gross Margin | 89.7% | 89.7% | - | - | - | - |
| Debt/Equity | 0.86 | 0.86 | 5.31 | 0.63 | 0.01 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -192M | -192M | -266M | -184M | -179M | -170M |
| Operating Margin | -101.2% | -101.2% | - | - | - | - |
| ROE | -145.2% | -251.1% | -1217.6% | -108.8% | -68.5% | -24.5% |
| Shares Outstanding | 65M | 65M | 61M | 58M | 52M | 50M |
| Metric | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | N/A | N/A | N/A | N/A | 190M | 190M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 89.7% | 89.7% |
| R&D | 23M | 50M | 109M | 90M | 104M | 109M | 135M | 238M | 167M | 167M |
| SG&A | 9.5M | 28M | 37M | 46M | 68M | 92M | 118M | 144M | 195M | 195M |
| EBIT | -32M | -78M | -146M | -137M | -170M | -179M | -184M | -266M | -192M | -192M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -101.2% | -101.2% |
| Net Income | -38M | -74M | -141M | -134M | -70M | -181M | -185M | -265M | -202M | -202M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -106.4% | -106.4% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||||
| ROIC | -21.4% | -30.1% | -49.5% | -79.3% | -24.3% | -68.5% | -66.9% | -53.5% | -109.2% | -74.3% |
| ROE | N/A | -30.1% | -50.1% | -80.5% | -24.5% | -68.5% | -108.8% | -1217.6% | -251.1% | -145.2% |
| ROA | -24.8% | -28.5% | -45.6% | -71.6% | -21.1% | -47.4% | -55.5% | -67.4% | -46.3% | -42.0% |
| Cash Flow | ||||||||||
| Op. Cash Flow | -29M | -62M | -123M | -122M | -146M | -173M | -136M | -114M | -116M | -116M |
| Free Cash Flow | -30M | -63M | -126M | -122M | -146M | -174M | -136M | -114M | -117M | -117M |
| Owner Earnings | -32M | -69M | -135M | -140M | -168M | -195M | -170M | -155M | -184M | -184M |
| CapEx | 133K | 722K | 3.4M | 214K | 434K | 281K | 47K | 47K | 953K | 953K |
| Maint. CapEx | 223K | 442K | 834K | 690K | 1.2M | 1.7M | 1.8M | 1.6M | 1.3M | 1.3M |
| Growth CapEx | 0 | 280K | 2.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 223K | 442K | 834K | 690K | 1.2M | 1.7M | 1.8M | 1.6M | 1.3M | 1.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.3M | 6.4M | 12M | 17M | 21M | 20M | 33M | 40M | 67M | 67M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 7.4M | 13M | 20M | 20M |
| Balance Sheet | ||||||||||
| Net Debt | N/A | N/A | -289M | -170M | -290M | -331M | -168M | -205M | -269M | 65M |
| Cash & Equiv. | 34M | 50M | 62M | 101M | 59M | 128M | 60M | 89M | 54M | 54M |
| Long-Term Debt | N/A | N/A | 3.1M | 2.6M | 1.9M | N/A | 106M | 108M | 101M | 101M |
| Debt/Equity | N/A | 0.06 | 0.01 | 0.02 | 0.02 | 0.01 | 0.63 | 5.31 | 0.86 | 0.86 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | -34.4 | -13.3 | -12.9 | -9.3 | -9.3 |
| Equity | N/A | 246M | 281M | 167M | 284M | 264M | 170M | 22M | 139M | 139M |
| Total Assets | 152M | 260M | 309M | 187M | 330M | 382M | 333M | 392M | 480M | 480M |
| Total Liabilities | N/A | 14M | 28M | 21M | 45M | 118M | 163M | 228M | 210M | 210M |
| Intangibles | N/A | N/A | N/A | N/A | 4.7M | 7.9M | 7.0M | 6.2M | 5.3M | 5.3M |
| Retained Earnings | -110M | -185M | -325M | -459M | -529M | -710M | -895M | -1.2B | -1.4B | -1.4B |
| Working Capital | 144M | 245M | 278M | 164M | 265M | 314M | 253M | 259M | 361M | 361M |
| Current Assets | 151M | 259M | 302M | 182M | 308M | 354M | 308M | 374M | 467M | 467M |
| Current Liabilities | 6.7M | 14M | 24M | 18M | 43M | 40M | 55M | 116M | 106M | 106M |
| Per Share Data | ||||||||||
| EPS | -2.83 | -2.39 | -3.86 | -3.04 | -1.40 | -3.47 | -3.20 | -4.34 | -3.11 | -3.11 |
| Owner EPS | -0.93 | -2.22 | -3.72 | -3.18 | -3.38 | -3.73 | -2.95 | -2.54 | -2.83 | -2.83 |
| Book Value | N/A | 7.95 | 7.71 | 3.78 | 5.71 | 5.06 | 2.94 | 0.36 | 2.14 | 2.14 |
| Cash Flow/Share | -0.86 | -2.00 | -3.37 | -2.77 | -2.94 | -3.32 | -2.36 | -1.87 | -1.78 | -3.09 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 34.4M | 31.0M | 36.5M | 44.1M | 49.7M | 52.2M | 57.7M | 61.0M | 64.9M | 64.9M |
| Valuation | ||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -32.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 2.0 | 5.7 | 16.0 | 156.0 | 51.4 | 47.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 27.0 | 34.9 |
| FCF Yield | N/A | N/A | N/A | N/A | -25.2% | -11.6% | -5.0% | -3.4% | -1.6% | -1.8% |
| Market Cap | 0 | 0 | 0 | 0 | 581M | 1.5B | 2.7B | 3.4B | 7.1B | 6.6B |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 19.21 | 14.53 | 24.27 | 46.69 | 78.88 | 102.10 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 11.68 | 28.72 | 47.08 | 55.59 | 110.00 | 102.10 |
RHYTHM PHARMACEUTICALS, INC. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 89.7%.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a debt-to-equity ratio of 0.86. This indicates moderate leverage.
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported earnings per share (EPS) of $-3.11 in its most recent fiscal year.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a return on equity (ROE) of -251.1%. A negative ROE may indicate losses or negative equity.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a 5-year average gross margin of 89.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 9 years of financial data for RHYTHM PHARMACEUTICALS, INC. (RYTM), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has a book value per share of $2.14, based on its most recent annual SEC filing.